Compare · ACHV vs KZR
ACHV vs KZR
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Kezar Life Sciences Inc. (KZR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ACHV focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances, while KZR focuses on Biotechnology: Pharmaceutical Preparations.
- ACHV is the larger of the two at $717.2M, about 13.3x KZR ($53.7M).
- ACHV has hit the wire 9 times in the past 4 weeks while KZR has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 7 for KZR).
- Company
- Achieve Life Sciences Inc.
- Kezar Life Sciences Inc.
- Price
- -
- -
- Market cap
- $717.2M
- $53.7M
- 1M return
- -
- -0.68%
- 1Y return
- -
- +14.78%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 0
- Recent ratings
- 11
- 7
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Kezar Life Sciences Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Latest ACHV
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel initiated coverage on Achieve Life Sciences with a new price target
- Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Latest KZR
- SEC Form 15-12G filed by Kezar Life Sciences Inc.
- SEC Form EFFECT filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Kezar Life Sciences Inc.
- Director Berger Franklin M closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- SEC Form 4 filed by Director Garner Elizabeth
- SEC Form 4 filed by Director Cooper Graham K
- Director Kauffman Michael closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Director Wallace Courtney
- CEO Kirk Christopher J. closing all direct ownership in the company (SEC Form 4) (tax liability)